Acceleron Pharma Commences Proposed Public Offering Of Common Stock
1/21/2014 9:38:23 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that it has commenced an underwritten public offering of $100 million of its common stock. All of the shares in the offering are to be sold by Acceleron.
Help employers find you! Check out all the jobs and post your resume.
comments powered by